文献速递前列腺癌

将预后DNA基因组分类器转化至临床:563例局限性前列腺肿瘤的回顾性验证

Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.
PubMed 文献 · Eur Urol · 2016-11-01

研究将100位点DNA分类器精简为31位点,在四个回顾性根治性前列腺切除术队列中验证其对生化复发和转移的预测能力,并与临床风险分层比较。31位点分类器可识别高生化复发风险(HR=2.73,p<0.001)和高转移风险(HR=7.79,p<0.001),与临床变量联合优于临床模型,并可用NanoString平台实施。

要点

  • 31位点基因组分类器与100位点分类器性能相似。
  • 分类器识别高生化复发风险(HR=2.73,p<0.001)和高转移风险(HR=7.79,p<0.001)。
  • 基因组分类器联合标准临床变量优于临床模型。

核心结论

  • 100位点和31位点基因组分类器能可靠识别局限性前列腺癌中治疗失败风险升高的患者。
  • NanoString检测可用于基于治疗前活检的临床-基因组评分,在前瞻性临床试验中筛选患者进行治疗降级或升级。

研究设计与样本

  • 四个回顾性根治性前列腺切除术标本队列被合并,另用102例患者队列通过NanoString平台检测31位点基因组分类器。
  • 基因组分类器评分用于预测生化复发(n=563)和转移(n=154),并与临床风险分层方案比较。

主要发现

  • 31位点基因组分类器性能与100位点分类器相似。
  • 31位点分类器识别出生化复发率升高的患者(风险比=2.73,p<0.001)。
  • 31位点分类器识别出最终发生转移的患者(风险比=7.79,p<0.001)。
  • 基因组分类器联合标准临床变量优于临床模型。
  • 31位点基因组分类器已通过NanoString检测实施。

临床怎么用

  • 作者认为NanoString检测可用于基于治疗前活检的临床-基因组评分,在前瞻性临床试验中筛选患者进行治疗降级或升级。

局限性

  • 研究仅限于回顾性队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Localized prostate cancer is clinically heterogeneous, despite clinical risk groups that represent relative prostate cancer-specific mortality. We previously developed a 100-locus DNA classifier capable of substratifying patients at risk of biochemical relapse within clinical risk groups. OBJECTIVE: The 100-locus genomic classifier was refined to 31 functional loci and tested with standard clinical variables for the ability to predict biochemical recurrence (BCR) and metastasis. DESIGN, SETTING, AND PARTICIPANTS: Four retrospective cohorts of radical prostatectomy specimens from patients with localized disease were pooled, and an additional 102-patient cohort used to measure the 31-locus genomic classifier with the NanoString platform. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The genomic classifier scores were tested for their ability to predict BCR (n=563) and metastasis (n=154), and compared with clinical risk stratification schemes. RESULTS AND LIMITATIONS: The 31-locus genomic classifier performs similarly to the 100-locus classifier. It identifies patients with elevated BCR rates (hazard ratio=2.73, p<0.001) and patients that eventually develop metastasis (hazard ratio=7.79, p<0.001). Combining the genomic classifier with standard clinical variables outperforms clinical models. Finally, the 31-locus genomic classifier was implemented using a NanoString assay. The study is limited to retrospective cohorts. CONCLUSIONS: The 100-locus and 31-locus genomic classifiers reliably identify a cohort of men with localized disease who have an elevated risk of failure. The NanoString assay will be useful for selecting patients for treatment deescalation or escalation in prospective clinical trials based on clinico-genomic scores from pretreatment biopsies. PATIENT SUMMARY: It is challenging to determine whether tumors confined to the prostate are aggressive, leading to significant undertreatment and overtreatment. We validated a test based on prostate tumor DNA that improves estimations of relapse risk, and that can help guide treatment planning.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Lalonde E, Alkallas R, Chua MLK, et al. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. Eur Urol. 2016. PMID: 27815082. doi:10.1016/j.eururo.2016.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。